IgG4-related Disease Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Zenas BioPharma, Horizon Therapeutics, Amgen, Sanofi, UMC Utrecht

The Key IgG4-related Disease Companies in the market include - Zenas BioPharma, Horizon Therapeutics, Amgen, Sanofi, UMC Utrecht, and others.

DelveInsight's "IgG4-related Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the IgG4-related Disease, historical and forecasted epidemiology as well as the IgG4-related Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the IgG4-related Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; IgG4-related Disease Market Forecast [https://www.delveinsight.com/sample-request/igg4-related-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the IgG4-related Disease Market Report:

*
The IgG4-related Disease market size was valued approximately USD 182 million in 2025 and is anticipated to grow with a significant CAGR of 34.60% during the study period (2020-2034)

*
In April 2025, IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory disorder that can affect multiple organs such as the pancreas, kidneys, and lungs. It is defined by the buildup of IgG4-positive plasma cells within tissues and increased IgG4 concentrations in the bloodstream.

*
In April 2025, Amgen received FDA approval for UPLIZNA, marking it as the first therapy available for adults with Immunoglobulin G4-related disease (IgG4-RD), a chronic inflammatory disorder impacting various organs. The treatment was granted Breakthrough Therapy Designation for its potential to address a significant unmet medical need.

*
The IgG4-Related Disease market, valued at approximately USD 170 million in 2024, is expected to expand at a notable CAGR throughout the forecast period (2020-2034).

*
In 2024, the United States accounted for the largest share of the market, totaling close to USD 90 million among the 7MM countries.

*
In 2024, there were approximately 148,970 diagnosed prevalent cases of IgG4-RD across the 7MM. Among these regions, the United States recorded the highest number of diagnosed prevalent cases.

*
In 2024, the United States had around 56,800 diagnosed prevalent cases of IgG4-RD, with numbers expected to rise over the forecast period from 2025 to 2034.

*
In 2024, the United States reported roughly 39,100 diagnosed prevalent cases of IgG4-RD in males and 17,700 cases in females.

*
In 2024, the total diagnosed prevalent cases of IgG4-RD in EU4 and the UK were around 53,550, with males representing approximately 38,850 cases and females about 14,750 cases.

*
We categorized patients into six age groups: 0-17, 18-29, 30-44, 45-64, 65-74, and greater than or equal to 75 years. Our analysis indicates that the highest proportion of diagnosed prevalent cases in Japan occurs in the greater than or equal to 75 years age group. In 2024, there were approximately 12,800 age-specific diagnosed prevalent cases of IgG4-RD in this group, with numbers expected to rise during the forecast period from 2025 to 2034.

*
Key IgG4-related Disease Companies: Zenas BioPharma, Horizon Therapeutics, Amgen, Sanofi, UMC Utrecht, and others

*
Key IgG4-related Disease Therapies: ZB012 (obexelimab), UPLIZNA (inebilizumab), rilzabrutinib, Filgotinib, and others

*
The IgG4-related Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage IgG4-related Disease pipeline products will significantly revolutionize the IgG4-related Disease market dynamics.

IgG4-related Disease Overview

IgG4-related disease (IgG4-RD) is a rare immune-mediated condition characterized by the infiltration of various organs with IgG4-positive plasma cells, leading to inflammation, fibrosis, and tissue damage. It can affect multiple organs simultaneously or sequentially, including the pancreas, salivary glands, lacrimal glands, kidneys, lungs, and lymph nodes.

Get a Free sample for the IgG4-related Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/igg4-related-disease-market [https://www.delveinsight.com/report-store/igg4-related-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

IgG4-related Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

IgG4-related Disease Epidemiology Segmentation:

The IgG4-related Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of IgG4-related Disease

*
Prevalent Cases of IgG4-related Disease by severity

*
Gender-specific Prevalence of IgG4-related Disease

*
Diagnosed Cases of Episodic and Chronic IgG4-related Disease

Download the report to understand which factors are driving IgG4-related Disease epidemiology trends @ IgG4-related Disease Epidemiology Forecast [https://www.delveinsight.com/sample-request/igg4-related-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

IgG4-related Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the IgG4-related Disease market or expected to get launched during the study period. The analysis covers IgG4-related Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the IgG4-related Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

IgG4-related Disease Therapies and Key Companies

*
ZB012 (obexelimab): Zenas BioPharma

*
UPLIZNA (inebilizumab): Horizon Therapeutics/Amgen

*
rilzabrutinib: Sanofi

*
Filgotinib: UMC Utrecht

Discover more about therapies set to grab major IgG4-related Disease market share @ IgG4-related Disease Treatment Landscape [https://www.delveinsight.com/sample-request/igg4-related-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the IgG4-related Disease Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key IgG4-related Disease Companies: Zenas BioPharma, Horizon Therapeutics, Amgen, Sanofi, UMC Utrecht, and others

*
Key IgG4-related Disease Therapies: ZB012 (obexelimab), UPLIZNA (inebilizumab), rilzabrutinib, Filgotinib, and others

*
IgG4-related Disease Therapeutic Assessment: IgG4-related Disease current marketed and IgG4-related Disease emerging therapies

*
IgG4-related Disease Market Dynamics: IgG4-related Disease market drivers and IgG4-related Disease market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
IgG4-related Disease Unmet Needs, KOL's views, Analyst's views, IgG4-related Disease Market Access and Reimbursement

To know more about IgG4-related Disease companies working in the treatment market, visit @ IgG4-related Disease Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/igg4-related-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. IgG4-related Disease Market Report Introduction

2. Executive Summary for IgG4-related Disease

3. SWOT analysis of IgG4-related Disease

4. IgG4-related Disease Patient Share (%) Overview at a Glance

5. IgG4-related Disease Market Overview at a Glance

6. IgG4-related Disease Disease Background and Overview

7. IgG4-related Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of IgG4-related Disease

9. IgG4-related Disease Current Treatment and Medical Practices

10. IgG4-related Disease Unmet Needs

11. IgG4-related Disease Emerging Therapies

12. IgG4-related Disease Market Outlook

13. Country-Wise IgG4-related Disease Market Analysis (2020--2034)

14. IgG4-related Disease Market Access and Reimbursement of Therapies

15. IgG4-related Disease Market Drivers

16. IgG4-related Disease Market Barriers

17. IgG4-related Disease Appendix

18. IgG4-related Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=igg4related-disease-market-insights-highlight-expanding-outlook-till-2034-delveinsight-evaluates-zenas-biopharma-horizon-therapeutics-amgen-sanofi-umc-utrecht]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.